Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20 years and above~* hemophilia A or B patients who reported painful (VAS ≥ 3) hemophilic arthropathy in ankles, elbows or knees for at least 6 months.~Exclusion Criteria:~* presence of joint infections~* any surgery on the joint in preceding 6 months~* intra-articular HA injection within the past 6 months~* history of rheumatoid arthritis,~* gouty arthropathy~* presence of neoplasm,~* allergy to shea nut oil production~* use of corticosteroids within 3 weeks prior to baseline and throughout the study~* use of anti-inflammatory agents 3 weeks prior to baseline and for the duration of the study,~* history of trauma associated with the signal joint,~* liver function tests greater than twice the upper limit of normal at baseline~* history of alcohol or substance abuse.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Shea nut oil (Type: EXPERIMENTAL): 100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
- Placebo (Type: PLACEBO_COMPARATOR): placebo which comprised 100% canola oil or starch mixed soybean oil

Based on this trial design, predict the completion outcome and termination type (if applicable).